Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19308626 | 0.70 | — | — | |
| SCHEMBL19363609 | 0.70 | GRIK1 (0.34) | GRIK1GRIK2 | |
| SCHEMBL21870645 | 0.69 | — | — | |
| SCHEMBL18103113 | 0.69 | — | — | |
| SCHEMBL19261536 | 0.69 | — | — | |
| SCHEMBL19441249 | 0.69 | — | — | |
| SCHEMBL24062722 | 0.68 | — | — | |
| SCHEMBL15576306 | 0.67 | — | — | |
| SCHEMBL25048054 | 0.67 | ADH1B (0.39) | — | |
| SCHEMBL8063186 | 0.65 | BACE1 (0.33) | GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-10632209-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190144442-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, MAP3K6, MAP3K1 | GRIK1 350/4885GRIK2 392/4885CTSD 3713/4885 |
| US-20190144442-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | ASH1L, DOT1L, ASH2L | GRIK1 2326/4885GRIK2 2709/4885CTSD 3250/4885 |
| US-10632209-B2 | ASH1L inhibitors and methods of treatment therewith | ASH1L, DOT1L, ASH2L | GRIK1 2326/4885GRIK2 2709/4885CTSD 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.